Catherine M. Avitabile, Delphine Yung, Stephanie Handler, Rachel K. Hopper, Jeff Fineman, Grace Freire, Nidhy Varghese, Mary Mullen, Usha S. Krishnan, Eric Austin, Lori Silveira, D. Dunbar Ivy
Children’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine. University of Washington School of Medicine. Medical College of Wisconsin. Stanford University School of Medicine. University of California San Francisco. Johns Hopkins All Children’s Hospital. Baylor College of Medicine and Texas Children’s Hospital. Boston Children’s Hospital and Harvard Medical School. Columbia University Irving Medical Center. Vanderbilt University Medical Center. University of Colorado School of Medicine.
United States
Journal of Pediatrics
J Pediatr 2023;
DOI: 10.1016/j.jpeds.2023.113639
Abstract
Objective: To evaluate the feasibility, tolerability, and adherence with wearable actigraphy devices among infants and children with pulmonary arterial hypertension (PAH).
Study design: This multi-center, prospective, observational study included children ages 0-6 years with and without PAH. Participants wore the ActiGraph wGT3X-BT on the hip and FitBit Inspire on the wrist during waking hours for 14 days. Steps, vector magnitude counts per minute (CPM), activity intensity, heart rate, and heart rate variability (HRV) were compared between groups.
Results: Forty-seven participants (18 PAH, 29 control) were enrolled from 10 North American sites. PAH patients were mostly functional class II (n=16, 89%) and treated with oral medications at the time of enrollment. The number of wear days was not significantly different between the groups (ActiGraph: 10 [95% CI 5.5, 12.2] in PAH vs. 8 [4, 12] in control, p=0.20; FitBit 13 [10, 13.8] in PAH vs. 12 [8, 14] in control, p=0.87). Complete data were obtained in 81% of eligible ActiGraph participants and 72% of FitBit participants. PAH participants demonstrated fewer steps, lower vector magnitude CPM, more sedentary activity, and less intense physical activity at all levels compared with control participants. No statistically significant differences in HRV were demonstrated between the two groups.
Conclusions: Measurement of physical activity and other endpoints using wearable actigraphy devices was feasible in young children with PAH. Larger studies should determine associations between physical activity and disease severity in young PAH patients to identify relevant endpoints for pediatric clinical trials.
Category
Diagnostic Testing for Pulmonary Vascular Disease. Non-invasive Testing
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Filed (PHiled). Greater than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No